Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Johnson Controls International PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.03 (market cap $39.89B), while Johnson Controls International PLC trades at $144.1 (market cap $87.13B). The key difference: Johnson Controls International PLC is far larger — about 2.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Johnson Controls International PLC pays a 1.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | JCI | |
|---|---|---|
Market Cap | $39.89B | $87.13B |
Sector | Health | Industrials |
52-Week High | $491.22 | $148.21 |
52-Week Low | $278.09 | $103.24 |
Enterprise Value | $38.15B | $95.96B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Johnson Controls International (JCI) trades at $142.81, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a net income margin of 14.45% and a consensus analyst price target of $153.67. Recent news highlights expansion in data center cooling and smart home markets, supported by a dividend of $0.40 per share payable in July 2026.
JCI's outlook is supported by earnings momentum and strategic acquisitions, but risks include high valuation multiples and bearish technical indicators. The stock offers potential upside to analyst targets, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
